Roche and Austria-based Hookipa Pharma tied up a licensing and research and development collaboration valued at more than $950 million focused on KRAS-mutated cancers.
Tag Archive for: HOOKIPA Pharma
On Monday, the high-profile partnership between Japan’s Daiichi-Sankyo and British-Swedish multinational AstraZeneca announced that the United States Food and Drug Administration has accepted their supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan), their HER2-directed candidate for unresectable or metastatic breast cancer.
